Cutting-edge system sterilizes duodenoscopes with low-temperature device
LOVELAND, CO, MYRTLE BEACH, SC, and QUEBEC CITY, Aug. 20, 2018 /CNW/ - TSO3 Inc. (TSX: TOS) ("TSO3" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, joins with UCHealth, a nationally recognized, nonprofit network of 10 acute care hospitals and more than 150 clinics throughout Colorado, southern Wyoming and western Nebraska, in announcing the first patient procedure in Colorado performed with a duodenoscope sterilized using the STERIZONE® technology.
"Providing our patients with the highest level of safety is central to every decision we make," said Darla Woodman, sterile processing nurse manager at UCHealth's Medical Center of the Rockies and Poudre Valley Hospital. "It is critical that our guidelines for reprocessing duodenoscopes ensure that each device is sterilized for every patient and every procedure."
Duodenoscopes are flexible endoscopes used during Endoscopic Retrograde Cholangiopancreatography (ERCP), which is a procedure that enables a physician to examine and take images of a patient's gallbladder, common bile duct, pancreas and liver.
"Reducing infection rates isn't dependent on technology alone, but through a team approach," added Brenda Lynch, gastrointestinal lab nurse manager at UCHealth's Greeley Surgery Center, Medical Center of the Rockies, and Poudre Valley Hospital. "Proper hand washing, wearing proper personal protective equipment and following hospital protocols all help lower the spread of bacteria and other infections. This sterilization system supplements our infection prevention tools that allow us to deliver a greater level of quality patient care."
In May 2018, U.S. regulators cleared TSO3's most recent 510(k) submission for the terminal sterilization of multi-channeled flexible endoscopes using the Company's STERIZONE® VP4 Sterilizer. The clearance for the STERIZONE® VP4 Sterilizer allows a hospital system like UCHealth to terminally sterilize gastrointestinal endoscopes that have dimensions within the cleared intended use.
"The recent and highly publicized infection outbreaks in the United States associated with the use of flexible endoscopes have highlighted the need for innovative approaches to reprocessing these complex devices," said R.M. (Ric) Rumble, TSO3's president and CEO. "We are pleased to be a part of the solution to this serious health problem, which can be eliminated only through the collaborative efforts of healthcare providers like UCHealth, in combination with medical device manufacturers, reprocessing device manufacturers, regulatory agencies, and professional societies."
According to the U.S. Centers for Disease Control ("CDC"), at least two million Americans are infected with antibiotic-resistant bacteria each year, and more than 23,000 of them die. By 2025, the CDC predicts more people will be diagnosed with an antibiotic-resistant infection than cancer. One type of antibiotic-resistant infection that was traced to contaminated endoscopes was caused by Carbapenem-resistant Enterobacteriace (CRE), a bacteria the CDC has designated as a "superbug." This superbug has a high mortality rate in infected patients. In 2015, the CDC reports 287 cases of CRE across the state of Colorado.
Carla Warner of North Carolina knows the devastating power of a "superbug." "Something I can't even pronounce destroyed my husband," said Warner, the widow of Bill Warner who contracted CRE following an ERCP procedure in North Carolina. Since that time, she has been a strong advocate for sterile devices. "The threat of antibiotic-resistant infections is absolutely not just hype, it is a very real issue affecting everyone. I'm hopeful we'll get to the point where everything that is used on a patient is safe." Click here to hear more of Warner's story.
About the STERIZONE® VP4 Sterilizer
The STERIZONE® VP4 Sterilizer is a low-temperature sterilization system that utilizes the dual sterilants of vaporized hydrogen peroxide (H2O2) and ozone (O3) to achieve terminal sterilization of heat and moisture-sensitive medical devices. Its single pre-programmed cycle can sterilize a large number and wide range of compatible devices, creating a cost-effective sterilization process with error-free cycle selection. The device's unique Dynamic Sterilant Delivery System™ automatically adjusts the quantity of injected sterilant based on the load composition, weight and temperature. This capability removes the guesswork and potential for human error, as there is no need to sort instruments and choose the appropriate cycles as with other machines.
The STERIZONE® VP4 Sterilizer is the only terminal sterilization method that is FDA cleared to sterilize multi-channeled flexible endoscopes (with a maximum of four channels) of up to 3.5 meters in length, such as video colonoscopes, duodenoscopes and gastroscopes - an industry first for any medical device sterilization process.
The STERIZONE® VP4 Sterilizer is also the only cleared low temperature sterilizer that can process a mixed load consisting of general instruments, single channel flexible endoscopes, and single or double channel rigid endoscopes in the same cycle with load weights of up to 75 lb. The ability to run mixed loads significantly reduces labor costs by minimizing the amount of instrument sorting required, while maximizing the device turns (more productivity from increased throughput capacity).
More information about the STERIZONE® VP4 Sterilizer is available through TSO3's website, under the Products section.
UCHealth is an innovative, nonprofit health system that delivers one of the highest quality medical care with an excellent patient experience. UCHealth combines Longs Peak Hospital, Yampa Valley Medical Center, Memorial Hospital, Poudre Valley Hospital, Medical Center of the Rockies, UCHealth Medical Group, Broomfield Hospital, Grandview Hospital and University of Colorado Hospital into an organization dedicated to health and providing unmatched patient care in the Rocky Mountain West. With more than 150 clinic locations, UCHealth pushes the boundaries of medicine, providing advanced treatments and clinical trials and improving health through innovation.
Founded in 1998, TSO3's activities encompass the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. TSO3 also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.
For more information about TSO3, visit the Company's website at www.tso3.com.
The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, the limited history of sales or distribution of the Company, the ability of the Company to obtain the required regulatory clearances to market its products, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. Although TSO3 believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. The complete versions of the cautionary note regarding forward-looking statements as well as a description of the relevant assumptions and risk factors likely to affect TSO3's actual or projected results are included in the Management's Discussion and Analysis for the year ended December 31, 2017, which is available on the Company's website. The forward-looking statements contained in this press release are made as of the date hereof, and TSO3 does not assume any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise unless expressly required by applicable securities laws.
SOURCE TSO3 Inc.
For further information: Company Contacts: R.M. (Ric) Rumble, President and CEO, Tel: 418 651-0003, Email: [email protected]; Glen Kayll, CFO, Tel: 418 651-0003, Email: [email protected]; Investor Relations: Gilmartin Group, Greg Chodaczek, Tel: 610-368-6505, Email: [email protected]; Renmark Financial Communications Inc., Barry Mire, Tel: 416 644-2020 or 514 939-3989, Email: [email protected]